WO2006061853A3 - Nouveaux composes erythropoietiques et leur procede de production - Google Patents

Nouveaux composes erythropoietiques et leur procede de production Download PDF

Info

Publication number
WO2006061853A3
WO2006061853A3 PCT/IN2005/000401 IN2005000401W WO2006061853A3 WO 2006061853 A3 WO2006061853 A3 WO 2006061853A3 IN 2005000401 W IN2005000401 W IN 2005000401W WO 2006061853 A3 WO2006061853 A3 WO 2006061853A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
erythropoietic
producing
erythropoietic compounds
novel
Prior art date
Application number
PCT/IN2005/000401
Other languages
English (en)
Other versions
WO2006061853A2 (fr
Inventor
Subhash V Kapre
Umesh S Shaligram
Original Assignee
Serum Inst India Ltd
Subhash V Kapre
Umesh S Shaligram
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serum Inst India Ltd, Subhash V Kapre, Umesh S Shaligram filed Critical Serum Inst India Ltd
Publication of WO2006061853A2 publication Critical patent/WO2006061853A2/fr
Publication of WO2006061853A3 publication Critical patent/WO2006061853A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention porte sur une érythropoïétine (EPO) non glycosylée ayant une meilleure stabilité et une demi-vie améliorée. C'est invention porte également sur un procédé de préparation d'une érythropoïétine (EPO) non glycosylée dont la stabilité et la 2006 sont améliorées. L'invention porte aussi sur un composé d'érythropoïétine comprenant une érythropoïétine humaine non glycosylée et Y-PEG_NHS de formule (I).
PCT/IN2005/000401 2004-12-10 2005-12-08 Nouveaux composes erythropoietiques et leur procede de production WO2006061853A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN978MU2004 2004-12-10
IN978/MUM/2004 2004-12-10

Publications (2)

Publication Number Publication Date
WO2006061853A2 WO2006061853A2 (fr) 2006-06-15
WO2006061853A3 true WO2006061853A3 (fr) 2007-03-15

Family

ID=36578320

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2005/000401 WO2006061853A2 (fr) 2004-12-10 2005-12-08 Nouveaux composes erythropoietiques et leur procede de production

Country Status (1)

Country Link
WO (1) WO2006061853A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006089228A2 (fr) * 2005-02-16 2006-08-24 Nektar Therapeutics Al, Corporation Conjugues d'une fraction d'epo et d'un polymere
GB0922354D0 (en) 2009-12-21 2010-02-03 Polytherics Ltd Novel polymer conjugates
CU20140003A7 (es) * 2014-01-08 2015-08-27 Ct De Inmunología Molecular Biofarmacuba Conjugado que comprende eritropoyetina y una estructura polimérica ramificada

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985002610A1 (fr) * 1983-12-13 1985-06-20 Kirin-Amgen, Inc. Production d'erythropoietine
WO2000032772A2 (fr) * 1998-11-30 2000-06-08 Eli Lilly And Company Composes erythropoietiques
WO2003055916A2 (fr) * 2001-12-21 2003-07-10 Maxygen Aps Fragments et conjugues de l'adiponectine
WO2004003176A2 (fr) * 2002-07-01 2004-01-08 The Kenneth S. Warren Institute, Inc. Cytokines protectrices des tissus recombinees et acides nucleiques codants associes pour la protection, la restauration et l'amelioration de cellules, de tissus et d'organes sensibles
WO2004019972A1 (fr) * 2002-08-29 2004-03-11 F. Hoffmann-La Roche Ag Utilisation d'erythopoietine
WO2004022577A2 (fr) * 2002-09-09 2004-03-18 Warren Pharmaceuticals, Inc. Erythropoietines a action longue qui maintiennent l'activite protectrice du tissu d'une erythropoietine endogene

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985002610A1 (fr) * 1983-12-13 1985-06-20 Kirin-Amgen, Inc. Production d'erythropoietine
WO2000032772A2 (fr) * 1998-11-30 2000-06-08 Eli Lilly And Company Composes erythropoietiques
WO2003055916A2 (fr) * 2001-12-21 2003-07-10 Maxygen Aps Fragments et conjugues de l'adiponectine
WO2004003176A2 (fr) * 2002-07-01 2004-01-08 The Kenneth S. Warren Institute, Inc. Cytokines protectrices des tissus recombinees et acides nucleiques codants associes pour la protection, la restauration et l'amelioration de cellules, de tissus et d'organes sensibles
WO2004019972A1 (fr) * 2002-08-29 2004-03-11 F. Hoffmann-La Roche Ag Utilisation d'erythopoietine
WO2004022577A2 (fr) * 2002-09-09 2004-03-18 Warren Pharmaceuticals, Inc. Erythropoietines a action longue qui maintiennent l'activite protectrice du tissu d'une erythropoietine endogene

Also Published As

Publication number Publication date
WO2006061853A2 (fr) 2006-06-15

Similar Documents

Publication Publication Date Title
HK1167658A1 (en) Composition for the preparation of 17-vinyl- triflates as intermediates 17--
CA2470183C (fr) Intermediaires pour la preparation d'arylsulphonamides et d'analogues
EA200401540A1 (ru) Спироиндолинпиперидиновые производные
JO2493B1 (en) New phenyl azatidinone with improved physical properties and methods of preparation of drugs containing it and its uses
PH12015501098A1 (en) Antituberculous composition comprising oxazole compounds
EP1634874A4 (fr) Derive d'imidazolidine
PT1466947E (pt) Composto azo
WO2007038277A3 (fr) Resolution de derives d'acide alpha-(phenoxy) phenylacetique avec des naphtyl-alkylamines
WO2006061853A3 (fr) Nouveaux composes erythropoietiques et leur procede de production
IS6435A (is) Aðferð til framleiðslu á sítalóprami
ATE280767T1 (de) Antidiabetische thiazolidindione und ihre herstellung
AU2003213422A1 (en) PROCESS FOR PRODUCING trans-4-AMINO-1-CYCLOHEXANECARBOXYLIC ACID DERIVATIVE
AU540658B2 (en) Cyclopropane derivatives
RS8604A (en) Process for the production of beraprost and its salts
UA85428C2 (ru) Способ получения с-2, с-3 замещенных n-алкилированных индолов, а также промежуточные соединения и способы их получения
EP0312269A3 (en) 3,5-dihydroxy-6,8-nonadienoic acids and derivatives as h3,5-dihydroxy-6,8-nonadienoic acids and derivatives as hypocholesterolemic agents ypocholesterolemic agents
DE69931807D1 (de) Herstellung von ascorbinsäure unter verwendung von hefe
EP1535920A4 (fr) Methode de preparation de derives de 1,3-benzodioxole-2-spiro-cycloalcane
WO2002059089A3 (fr) Procede de preparation d'analogues d'indene heterocycliques
NO20033049L (no) Fremgangsmåte for fremstilling av (+/-) trans-4-p-fluorfenyl- 3-hydroksymetyl-1-metylpiperidin
IE800234L (en) 7-acylindolin-2-ones and 7-acylindolines.
TW200621807A (en) Cellulose derivative composition, cellulose derivative film and trialkoxybenzoic acid deriv ative compound
EP1698617A4 (fr) Procede de production d'un compose de cycloalkylidene et de bisoxazoline optiquement actif et ses intermediaires
DE69511449D1 (de) Octahydro-2-Naphthalincarbonsäure-Derivate, ihre Herstellung und Verwendung
WO2003018572A1 (fr) 3-(n-alcoxycarbonyl-n-methyl)amino-1-alcoxycarbonyl-oxy-(2-thienyl)propanes et procede de preparation de 3-(n- methylamino)-1-(2-thienyl)-propan-1-ol avec ce compose

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 05849152

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 05849152

Country of ref document: EP

Kind code of ref document: A2